Emcure Pharmaceuticals Limited · NSE:EMCURE
Emcure Pharmaceuticals — Q1 FY27 Earnings Presentation
10 slides from Emcure Pharmaceuticals's earnings presentation, Aug 6, 2026
Slide 1: Intimation of Presentation on Unaudited Financial Results
Emcure Ref: EPL/CS/SE/0066/2026 Date: August 06, 2026 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Si
Slide 2: Emcure Results Q1FY27
Emcure Results Q1FY27 ( Aug 06, 2026 = \ | al
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute “forward-looking statements.” These statements are based on Emcure Pharmaceuticals Limited’s current expectations, assumptions, and projections about futur
Slide 4: Q1 FY27 – Corporate Updates
Q1 FY27 – Corporate Updates Mr. Satish Mehta to take over as Chairman, in addition to his existing role as Managing Director & CEO (post the conclusion of the upcoming AGM) Mr. Samit Mehta appointed COO of Emcure Pharmaceuticals ▪ Gets broader oversight of the Group’s R&D, operations and licensing a
Slide 5: Q1 FY27 - Key Financial Snapshot
Q1 FY27 - Key Financial Snapshot Key Highlights – Q1FY27 ▪ Strong all-round performance with increased Revenue / Growth EBITDA / Margin PAT / Margin contribution from the International business (58%) ▪ International Business revenue up 34.2% YoY with 25,804 / 22.8% 5,080 / 19.7% 2,925 / 11.3% strong
Slide 6: Q1FY27 – Other Financial Data Points
Q1FY27 – Other Financial Data Points R&D (INR Mn) RoCE1 R&D as % of Revenue 3.6% 4.2% 3.5% 3.5% 23.7% 23.4% 3,835 22.0% 2,875 730 904 FY25 FY26 Q1FY26 Q1FY27 31-Mar-2025 31-Mar-2026 30-Jun-2026 CAPEX (INR Mn) Net debt (INR Mn) Net debt to TTM2 0.3 0.7 0.6 EBITDA (x) 4,342 10,538 11,026 3,763 4,883 9
Slide 7: Q1 FY27 – Domestic Business Performance
Q1 FY27 – Domestic Business Performance Domestic (INR Mn) Key Highlights ▪ Performance in line with expectations, supported by 40,270 normalized Zuventus performance. 36,597 ▪ Growth across CNS, women’s health franchise and cardio- metabolics range led by key brands like Tenectase, Orofer XT, Orofer
Slide 8: Q1 FY27 – International Business Performance
Q1 FY27 – International Business Performance Europe (INR Mn) Canada (INR Mn) RoW (INR Mn) 18,498 14,869 18,399 14,738 12,520 15,105 5,367 3,425 4,266 3,603 5,218 4,042 FY25 FY26 Q1FY26 Q1FY27 FY25 FY26 Q1FY26 Q1FY27 FY25 FY26 Q1FY26 Q1FY27 ARV1 ▪ Strong EU and steady U.K. performance led ▪ Healthy g
Slide 9: P&L Summary | Q1 FY27
P&L Summary | Q1 FY27 INR Mn except % Q1 FY27 Q1 FY26 YoY % Q4 FY26 QoQ % FY26 Revenue from Operations 25,804 21,005 22.8% 24,697 4.5% 92,035 Domestic 10,953 9,935 10.2% 9,772 12.1% 40,270 International 14,851 11,070 34.2% 14,925 -0.5% 51,766 RoW 5,218 3,603 44.8% 5,557 -6.1% 18,399 EU 5,367 4,042 3
Slide 10: For further information / institutional investor queries
For further information / institutional investor queries Contact: Saurabh Paliwal Email: Investor.Relations@emcure.com Q1 FY27 CONFERENCE CALL DETAILS Date: Thursday, August 6, 2026 Time: 04:00 pm IST To Register: Click here to register Registered Office Plot No. P-1 and P-2, IT-BT Park, Phase II, M
Emcure Pharmaceuticals — Q1 FY27 Earnings Presentation on 6ix